Fulltext

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer

Yoshino T 1 , Cervantes A 2 , Bando H 3 , Martinelli E 4 , Oki E 5 , Xu RH 6 Show all authors , Mulansari NA 7 , Govind Babu K 8 , Lee MA 9 , Tan CK 10 , Cornelio G 11 , Chong DQ 12 , Chen LT 13 , Tanasanvimon S 14 , Prasongsook N 15 , Yeh KH 16 , Chua C 12 , Sacdalan MD 17 , Sow Jenson WJ 18 , Kim ST 19 , Chacko RT 20 , Syaiful RA 21 , Zhang SZ 22 , Curigliano G 23 , Mishima S 3 , Nakamura Y 3 , Ebi H 24 , Sunakawa Y 25 , Takahashi M 26 , Baba E 27 , Peters S 28 , Ishioka C 29 , Pentheroudakis G 30

Affiliations 

  • 1 Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: tyoshino@east.ncc.go.jp
  • 2 Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
  • 3 Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
  • 4 Oncology Unit, Department of Precision Medicine, Università degli Studi della Campania 'L. Vanvitelli', Naples, Italy
  • 5 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • 6 Department of Medical Oncology, Sun Yat-Sen University Cancer Center and State Key Laboratory of Oncology in South China, Guangzhou, China
  • 7 Hematology-Medical Oncology Division, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital/Universitas Indonesia, Jakarta, Indonesia
  • 8 Department of Medical Oncology, HCG Hospital and St. John's Medical College, Bengaluru, India
  • 9 Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
  • 10 Department of Oncology and Nuclear Medicine, Thomson Hospital Kota Damansara, Selangor, Malaysia
  • 11 Department of Medical Oncology, University of the Philipppines-Philippine General Hospital, St. Lukes Cancer Institute-Global City, The Philippines
  • 12 Division of Medical Oncology, National Cancer Centre Singapore, Singapore
  • 13 Department of Internal Medicine, Kaohsiung Medical University Hospital and Centre for Cancer Research, Kaohsiung Medical University, Kaohsiung; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
  • 14 Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok
  • 15 Division of Medical Oncology, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand
  • 16 Department of Oncology, National Taiwan University Hospital, Taipei; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan
  • 17 Department of Surgery, University of the Philippines-College of Medicine and University of the Philippines-Philippine General Hospital, Manila, The Philippines
  • 18 Department of Radiotherapy & Oncology, Aurelius Hospital, Nilai, Malaysia
  • 19 Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Centre, Seoul, South Korea
  • 20 Department of Medical Oncology, Christian Medical College, Vellore, Tamil Nadu, India
  • 21 Department of Surgery, Dr Cipto Mangunkusumo National General Hospital, University of Indonesia, Jakarta, Indonesia
  • 22 Department of Colorectal Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
  • 23 Istituto Europeo di Oncologia, IRCCS, Milan; Department of Oncology and Haematology, University of Milano, Milan, Italy
  • 24 Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya
  • 25 Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki
  • 26 Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai
  • 27 Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • 28 Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland
  • 29 Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan
  • 30 ESMO, Lugano, Switzerland
ESMO Open, 2023 Jun;8(3):101558.
PMID: 37236086 DOI: 10.1016/j.esmoop.2023.101558

Abstract

The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer (mCRC), published in late 2022, were adapted in December 2022, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with mCRC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with mCRC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and the Japanese Society of Medical Oncology (JSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian countries. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with mCRC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling and age and stage at presentation, coupled with a disparity in the drug approvals and reimbursement strategies, between the different countries.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications